Fluoroquinolone therapy for the prevention of multidrug-desistant tuberculosis in contacts: A cost-effectiveness analysis

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 2, 2015, Pages 229-237

  Fox, Gregory J ^a,b   Oxlade, Olivia ^a,b   Menzies, Dick ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antitubercular agents; Cost effectiveness analysis; Latent tuberculosis infection; Multidrug resistant tuberculosis

Indexed keywords

QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MODELS, ECONOMIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84938149652     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201501-0069OC     Document Type: Article

References (58)

1. World Health Organization. Global tuberculosis report. Geneva: World Health Organization; 2014.
2. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
3. World Health Organization. Multidrug-resistant TB (MDR-TB): 2013 update. Geneva: World Health Organization; 2013.
4. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One 2013;8:e54587.
5. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007;11:1314-1320.
6. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitnick CD. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011;377:147-152.
7. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;(2):CD001363.
8. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven- Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-2166.
9. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014;161:419-428.
10. European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm: European Centre for Disease Prevention and Control; 2012.
11. Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM, Heetderks A, Mase S. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014;18:912-918.
12. Seddon JA, Hesseling AC, Finlayson H, Fielding K, Cox H, Hughes J, Godfrey-Faussett P, Schaaf HS. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013;57:1676-1684.
13. Gillespie SH, Crook A, Mchugh T, Mendel C, Meredith S, Murray S, Pappas F, Phillips P, Nunn A. REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-1587.
14. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582.
15. Saito H, Sato K, Tomioka H, Dekio S. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuber Lung Dis 1995;76:377-380.
16. Tsukamura M. Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice. Am Rev Respir Dis 1985;132:915.
17. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010;33:353-369.
18. Langendam MW, Tiemersma EW, van der Werf MJ, Sandgren A. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review. PLoS One 2013;8:e53599.
19. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. Geneva: World Health Organization; 2014.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization; 2011.
21. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
22. Curry International Tuberculosis Center, California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians, 2nd ed. 2011.
23. Curry International Tuberculosis Center, California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 1st ed. 2008.
24. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2014.
25. Howden L, Meyer J. Age and sex composition: 2010. Washington, DC: U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau; 2011.
26. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-370.
27. Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998;158:465-469.
28. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012.
29. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al.; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
30. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
31. Cremades R, Rodríguez JC, García-Pachón E, Galiana A, Ruiz-García M, López P, Royo G. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother 2011;66:2281-2283.
32. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, et al.; TB Epidemiologic Studies Consortium. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis 2014;20:812-821.
33. McEvoy G, editor; American Society of Health System Pharmacists. American Hospital Formulary Service drug information. Bethesda, MD: American Society of Hospital Pharmacists; 2014.
34. U.S. Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. Consumer price index. Washington, DC: United States Department of Labor; 2014 [accessed 2014 Dec 11]. Available from: http://www.bls.gov/home.htm
35. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, Kamlet M, Russell L; Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
36. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, et al.; Global Preserving Effective TB Treatment Study (PETTS) Investigators. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014;59:1049-1063.
37. Chien JY, Lai CC, Tan CK, Yu CJ, Hsueh PR. Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan. Clin Infect Dis 2013;56:1054-1055.
38. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12:744-751.
39. Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med 2013;5:180ra49.
40. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, Mosimaneotsile B, Motsamai OI, Bozeman L, Davis MK, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588-1598.
41. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986;133:431-436.
42. Rouzier VA, Oxlade O, Verduga R, Gresely L, Menzies D. Patient and family costs associated with tuberculosis, including multidrugresistant tuberculosis, in Ecuador. Int J Tuberc Lung Dis 2010;14: 1316-1322.
43. Holland DP, Sanders GD, Hamilton CD, Stout JE. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One 2012;7:e30194.
44. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, et al.; OFLOTUB/ Gatifloxacin for Tuberculosis Project. A four-month gatifloxacincontaining regimen for treating tuberculosis. N Engl J Med 2014;371:1588-1598.
45. Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014;26:149-153.
46. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448-1452.
47. Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Risk of tuberculosis after recent exposure: a 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014;190:1044-1052.
48. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees: a five-year surveillance study. Am Rev Respir Dis 1988; 137:805-809.
49. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974;110:572-580.
50. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 1975;101:363-382.
51. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
52. Arias E. United States life tables, 2009. Natl Vital Stat Rep 2014;62:1-63.
53. Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis 2013;17:1328-1335.
54. Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, Fitzgerald JM. Health state utilities in latent and active tuberculosis. Value Health 2008;11:1154-1161.
55. Centers for Disease Control and Prevention. Reported tuberculosis in the United States 2013. Atlanta: U.S. Department of Health and Human Services; 2014.
56. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-168.
57. Conde M, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-1189.
58. Norton BL, Holland DP. Current management options for latent tuberculosis: a review. Infect Drug Resist 2012;5:163-173.